Information regarding the generic availability of Dovato is limited.
When does Dovato's patent expire?
The specific patent expiry dates for Dovato are not publicly available. Patent information for drugs can be complex, involving multiple patents for the drug substance, formulation, and manufacturing processes. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be a resource for detailed patent timelines.
What are the active ingredients in Dovato?
Dovato is a fixed-dose combination of two antiretroviral medications: dolutegravir and lamivudine [1]. Dolutegravir is an integrase inhibitor, and lamivudine is a nucleoside reverse transcriptase inhibitor.
Who manufactures Dovato?
Dovato is manufactured by ViiV Healthcare [1].
What is Dovato used to treat?
Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents who weigh at least 88 pounds (40 kg) [1]. It is used in individuals with no known history of resistance to either dolutegravir or lamivudine.
What are the alternatives to Dovato?
Alternative HIV treatment options include other single-tablet regimens containing different combinations of antiretroviral drugs, as well as multi-pill regimens. The choice of treatment depends on individual patient factors, including resistance patterns, comorbidities, and potential drug interactions.
What is the typical cost of Dovato?
Pricing for prescription medications can vary significantly based on insurance coverage, pharmacy, and geographic location. Specific cost details for Dovato are best obtained by consulting with a healthcare provider or a pharmacy.
Are there any generic versions of Dovato currently available?
As of current information, generic versions of Dovato are not widely reported as being available. The development and approval of generic drugs typically occur after the expiration of relevant patents and market exclusivity periods.